Moderna norovirus vaccine trial on hold by US FDA over neurological side effect
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Barclays Downgrades Moderna (MRNA) to Equalweight
February 18, 2025 5:13 AM ESTBarclays analyst Gena Wang downgraded Moderna (NASDAQ: MRNA) from Overweight to Equalweight with a price target of $45.00 (from $111.00).
The analyst comments "Key takeaways. Following MRNA pre-announcement (see note), 4Q24 financial updates were largely incremental, except disclosure of norovirus Ph3 NOVA-1 (NCT06592794) clinical hold... More
Moderna (MRNA) PT Lowered to $25 at Wolfe Research
February 14, 2025 2:07 PM ESTWolfe Research analyst Alexandria Hammond lowered the price target on Moderna (NASDAQ: MRNA) to $25.00 (from $35.00) while maintaining a Underperform rating.
The analyst comments "We revised our FY2025 rev/EPS #'s downward. Cost management, Roivant litigation (potential trial in Sept), CMV... More
